Background: There is currently no known cure for multiple sclerosis (MS). Four stakeholders play a major role in MS: healthcare professionals, regulators, payers and patients. Objective: In Europe, patients are represented by the European Multiple Sclerosis Platform (EMSP), which aims to improve MS management and patients' quality of life. Results: The EMSP has recently shown that there are major disparities in Europe in terms of access to care and treatment. Implementing the Code of Good Practice and a standardised MS nurse training may be useful in harmonising MS management across Europe. Additionally, the burden for novel therapeutic options to be approved by regulatory agencies has to decrease in order to provide faster access of treatment to patients. Data collection (e.g. national registers) also appears crucial to help research and shape the most effective policy in each country. Finally, people with MS should get appropriate (financial) support in order to complete their studies and find a job, as their active participation in society requires proper access to education and employment. Moreover, as they are the ones affected by MS, they seem to be best placed to represent themselves and their needs and should be consulted more often during decision-making processes by policy makers, regulators and payers.
Introduction
Multiple sclerosis (MS) is a complex neurological condition 1 which affects people in various ways. 2 Symptoms range from fatigue and depression to severe mobility problems and blindness in extreme cases. Most people are diagnosed between the ages of 20 and 40 years, when they are at the peak of their productive life, and half of them experience unemployment within 3 years after diagnosis on average. 3 There is currently no cure for MS, but this debilitating progressive condition can be managed through specialised care, starting with early diagnosis and continuing with person-centred therapies 4 and appropriate medication (e.g. disease-modifying drugs (DMDs)). However, a tremendous variation in access to optimal treatment and care has been observed across Europe.
In order to better meet the patients' needs, good communication and collaboration between the different stakeholders is essential. This includes MS patients, their caregivers, policy makers, healthcare professionals, researchers, regulators and payers. Therefore, two Pan-European MS Multi-stakeholder Colloquia were organised on 23-24 May 2014 5 and 15-16 May 2015 6 in Brussels to enhance cross-talk and collaboration between several main stakeholders: patients, clinicians, regulators and payers. The programme of the first 2014 Colloquium 5 developed by the chair and scientific committee aimed at prioritising actions needed to improve the quality of and access to care and treatment. After introductory presentations of experts from the different stakeholder platforms, the audience was asked to pick from a list of potential calls to action, those which deserved in their opinion highest priority. The outcome of the polling was used as input for further discussions with the speakers, a group of panel members and the audience, which formed the basis for the development of 10 integrated Calls to Action. 7 At the second 2015 Colloquium, 6 guidance propositions/ recommendations for the Calls to Action as prepared by four working groups prior to the Colloquium and how accelerating adoption of innovation can lead to better care in MS were discussed. In this paper, we will consider some of the European Multiple Sclerosis Platform (EMPS) initiatives synergic to the multistakeholder initiatives and we will elaborate on the modalities to improve the access to care.
The EMSP: vision, mission and key opportunities
The EMSP is an umbrella organisation that was created 25 years ago to give a voice to patients with MS. 8 It now counts 39 members (i.e. MS societies) based in 34 countries. The objective of the EMSP is to shape a world without MS and improve the patients' quality of life as well as access to care, treatment and employment. The EMSP acts as an interface between national MS societies and European bodies (e.g. the European Parliament, the European Commission (EC), the European Medicines Agency (EMA), the European Academy of Neurology, etc.) and currently has 16 partners in the industry. Additionally, with six on-going flagship projects, the EMSP is considered as a leader of innovative MS-related patient-focused projects at the European level ( Figure 1 ).
The European Register for Multiple Sclerosis: a much-needed data collection
The European Register for Multiple Sclerosis (EUReMS) is a 3-year project initiated in 2011 and led by the EMSP. 9 It aims to develop a tool for assessing, comparing and enhancing the status of people with MS throughout the European Union (EU). Sets of data are extracted from existing European registers and put in a common format. The intention is to use this large dataset to address research questions on a European level across four areas of interest: epidemiology (Epi), DMD access and long-term efficacy (DMD), patient-reported outcomes (PRO) and socio-economic studies (SES). 11, 12 The project has reached the final stage of its first development phase.
There is hope that the practical use of these data will be explored within the Innovative Medicines Initiative 2 (IMI2), which is a joint technology initiative bringing together EMSP, pharmaceutical companies, universities, healthcare professional organisations, innovative subject-matter experts and regulators (EMA). EUReMS' long-term objectives are to monitor trends in MS epidemiology, to integrate PRO measures and to enable reliable comparisons across European countries through standardisation (e.g. methodology, data collection, analytical tools).
Promising efforts are going on by a multi-stakeholder consortium led by Karolinska Institutet and EMSP to join 16 registries in Europe into the European Network of Multiple Sclerosis (EuNetMus) Patient Registries, Cohorts and Databases with the aim to harmonise data collection and analysis approaches to match currently unmet needs of scientists, regulators, payers and patient advocates for a deeper evidence base for their decisions. Reproduced with permission from the EMSP. 8 MS: multiple sclerosis; EUReMS: European Register for Multiple Sclerosis; 9 MS Nurse PRO: multiple sclerosis nurse professional. 10 The MS Barometer: a benchmarking tool Launched in 2008, the MS Barometer is a tool that provides data related to the management of MS and the quality of life of MS patients. 13 The objective is to obtain an accurate picture of the situation of people living with MS across Europe. This is done by collecting answers from clinicians and patient organisations to key questions (a survey is conducted every 2 years) regarding obstacles and barriers that people with MS face in Europe.
The online questionnaire covers seven areas pertaining to the MS environment at the national level: (1) access to treatment and care (19 questions); (2) research (three questions); (3) education, employment and job retention (12 questions); (4) involvement and empowerment of people with MS (seven questions); (5) reimbursement of costs related to MS (six questions - Figure 2 ); (6) data collection at national level (five questions); (7) medication coming to the market (three questions). A high score in each category indicates that the atmosphere for patients is fair (i.e. the quality of policies and programmes effectively reduces the pressure on their daily lives). The scoring system also identifies gaps in service provision that place undue pressure on people with MS. The maximum overall score is 245 points.
The results from the 2013 MS Barometer are available online. 13 In the foreseeable future, it is the intention of the EMSP to upload the core data on a website. Each country would have its own webpage providing national figures on, for example, prevalence of MS, cost of MS to society, number of patients who have access to treatment, proportion of MS patients who are working, number of patients who have access to DMDs compared with other European countries, etc.
MS nurse PRO: an online training course
Given the inconsistencies in MS nursing observed across Europe, there is an urgent need for a pan-European harmonisation of MS nursing. Such a harmonisation, if done to the top, would indirectly improve the quality of care for people with MS and their families. To date, MS Nurse PROfessional 10 is the first and only European Continuing Medical Education (CME)accredited MS Nurse online training course. It is currently available in seven languages (English, Spanish, German, Czech, French, Dutch and Italian). It consists of a modular training curriculum, which aims to support the evolving role of European MS nurses. It focuses on the core competences of these specialised nurses by addressing topics such as advocacy, health education, symptom and treatment management. Two The EMSP hopes that this course will provide a benchmark for MS nursing practice and care across Europe. It seems to have spread quite well over the last year, as it has only been launched in five countries and already counts 712 registered users across 24 countries.
Additionally, a MS Nurse consensus paper 14 
'Under Pressure' project: a photojournalistic translation of MS Barometer findings
The 'Under Pressure' project is also an EMSP initiative. 16 More than 10,000 photos were collected from MS patients throughout Europe. A selection of the best 600 pictures was made to create brochures and panel exhibitions that can be used in all kinds of settings. Videos were also part of the project with one short film collected from each participating country (12 in total but only five videos gathered so far). The ultimate goal of this project is to raise awareness about the existing inequalities between MS patients regarding access to treatment and care in Europe. It is also a way for people with MS to tell their own story and visualise how MS impacts on their life. 16 'Believe and Achieve': a way to create work opportunities for young people The 'Believe and Achieve' project was initiated in 2014. 17 This concept aims to create work opportunities for young people with MS through partnerships with pharma-and non-pharmaceutical companies across Europe. The pilot programme comprises 10 employers who committed to offering a paid 12-month internship placement to one young person with MS. Participating employers are provided with guidance on staff retention. In addition, information and support is offered to the young interns. The benefits of this type of agreement are mutual ( Figure 3 ). Lastly, this initiative also helps to raise awareness regarding employment issues encountered by people with MS in European countries.
Successful implementation of a better access to MS treatment in Poland
The Polish MS society (i.e. PTSR standing for 'Polskie Towarzystwo Stwardnienia Rozsianego') is the only all-Polish, non-governmental organisation The MS Barometer created by the EMSP showed that there are important disparities in the way MS is managed across Europe. In one of the most important sections of the MS Barometer (i.e. access to treatment and therapies), Poland only rated 22 out of a possible 70 points ( Figure 5 ) -Belarus was the only country with a score below 22. 13 It is of note that Poland remains one of the few European countries (with Ireland and Belarus) in which DMD therapy duration is not only influenced (as in most European countries) but also determined by non-medical factors, such as the reimbursement policy based on very limited budgets. Until relatively recently (2011), only 6%-7% of MS patients had access to DMDs. A 3-year reimbursement limit was applied to first-line therapies for each patient. Second-line options were not reimbursed. Moreover, patients outside a 16-to 40-age bracket were less likely to obtain access to treatment. Finally, there was no national register of the MS population in Poland. Nowadays, it is estimated that 17% of people with MS receive DMDs across Poland. 13 During the last 5 years, measures have been taken to improve access to treatment of MS patients in Poland. The reimbursement limit was first pushed from 3 to 5 years for available first-line treatments (i.e. interferons and glatiramer acetate) and recently this limit was abolished completely. Fingolimod and natalizumab are now both approved and reimbursed as second-line treatment for MS patients, with a 5-year limit. The lower age limit to enter the programme is now 12 years for first-line treatments, 18 years for second-line treatments and the upper limit has disappeared. Several actions undertaken by PTSR over the last 3 years will certainly have contributed to this improved current situation in Poland. These include (1) acting as a consultation body for the Polish Health Technology Assessment (HTA) agency, (2) organising debates and high-level round tables, (3) setting up a press conference at the Polish Press Agency and (4) holding a debate at one of the main Polish opinion shaping newspaper (i.e. Rzeczpospolita). During each event, MS Barometer data were presented. Current efforts of the PTSR are focussing on prolonging the duration of second-line therapy (i.e. to more than 5 years).
Improving access to treatments and care by developing the appropriate (societal) policies
In 2010, the mean life expectancy of people living in countries of the Organisation for Economic Co-operation and Development (OECD) ranged from 78.7 and 83.0 years (the highest observed in Japan, the lowest observed in the United States). Interestingly, the highest healthcare expenditures were observed in the United States (17.6% of the gross domestic product (GDP) versus 8.9%-12.0% in other countries). Consequently, it seems that the most expensive healthcare system is not necessarily the most effective one.
When looking on the MS Barometer 2013 results, 13 it seems that at least today access to treatment and care may not be an issue in central and northern Europe, but there is a large room for improvement in healthcare systems currently in place in southern and eastern Europe (as shown by the MS example from Poland). However, due to demographic changes (e.g. ageing population), the use of innovative medical techniques, the larger number of available treatments as well as the inefficiency of the healthcare systems in place, the costs of healthcare systems are constantly rising. This may impact access to treatment and care, in particular for chronic or orphan diseases, in the future, also in central and northern Europe.
The current decision-makers in healthcare: politicians
Although politicians are usually main decision-makers in healthcare, they are rarely experts in this field. Moreover, due to the complexity of the subject, they often refrain themselves from making any changes as existing issues cannot be fixed easily (or quickly). So politicians may not be the most appropriate people to carry the responsibility of initiating, developing and/ or improving healthcare systems (or health policies). It might be more interesting to have an independent committee in charge of elaborating concrete solutions and concepts. The resulting projects could then be discussed with the main stakeholders of the healthcare system and compared to existing projects in other countries, before being submitted to politicians to take decisions/actions. Indeed, presenting realistic facts as well as promising initiatives would help politicians to better comprehend crucial information and make more informed decisions. To successfully promote new concepts and policies to politicians, it is key to highlight their specific advantages (e.g. improved patient safety, increased efficiency, better quality, lower costs). It should also be stressed that improving the quality of healthcare indirectly leads to decreased costs for individuals and society. This was also considered a point of high priority by the participants of the MS Multi-stakeholder Colloquium from 23-24 May 2014 in Brussels ( Figure 6 ).
Finally, policies should not solely be based on medical considerations. Prevention, research and social support activities also need to be covered. Indeed, paramedical and social assistance are generally as important as medications to patients' welfare.
Hurdles to overcome for improving access to care and treatment for chronic diseases
Integrated care may be one approach to make healthcare systems more efficient and less expensive. According to the World Health Organization (WHO), integrated care is a concept bringing together inputs, delivery, management and organisation of services related to diagnosis, treatment, care, rehabilitation and health promotion. Integration is a means to improve services in relation to access, quality, user satisfaction and efficiency. 18 Numerous integrated care models are already effective in practice, but not in the field of chronic and orphan diseases. The survival of such an integrated care system will rely on several characteristics. Patient paths and standard operating procedures should be defined and coordinated in diagnosis and care settings. Early and quick diagnosis should be made possible. Specialists and general practitioners should be working together with centres of excellence in which knowledge is concentrated. Patients should be included into an organised chain of treatment in order to find the best doctor for their medical condition. A structured cooperation with hospitals needs to exist. Multiple examinations should be avoided whenever possible as they are expensive. Standardised follow-up examinations must be performed to help avoiding consecutive sickness. In Switzerland, the government was in favour of implementing a new integrated care system. In June 2012, people were asked to give their opinion regarding this potential implementation: 76% of them were against this project. Fear was hidden behind this rejection: fear of losing the freedom of choice (for patients), fear of managing 'glassy' patients (for doctors) and fear of decreasing their turnover (for specialists). The authorities seem to have failed in convincing the population that the advantages of integrated care would take over its disadvantages. Nevertheless, during the polling at the MS Multi-stakeholder Colloquium, 'adoption of integrated care in diagnosis and care' ended up being rated as the highest priority area ( Figure 6 ).
Health insurance companies may also form a hurdle for implementing integrated care and/or improving access to long-term treatment for chronic conditions. This is because if an insurance company would support integrated care systems and promote high quality and convenient therapies, they would indirectly get penalised for it. Indeed, they would attract many patients with chronic illnesses and covering their treatment costs would be prohibitively expensive. So, health insurance companies have currently no interest (or incentive) to optimise services for chronically ill patients. A solution would be to establish an intercompany 'compensation' scheme for high-risk patients. For example, in Switzerland, every insurance company contributes to a common fund. Companies with a larger number of low-risk clients (e.g. young people) have to pay more than others. The fund is then redistributed to companies insuring chronically-ill patients. This 'compensation' scheme appears to be an acceptable way to solve a major issue.
How to boost innovation for improving access to care and treatment? It appears necessary for innovation to be established and brought to patients a lot faster. Easy access to new methods should be encouraged. Indeed, new technologies such as the electronic medical record (EMR), telemedicine and telemonitoring seem especially useful in the management of chronic diseases.
Additionally, procedures for access to novel drugs should be simplified and accelerated. Fast-track drug admission is needed as well as concerted procedures (Food and Drug Administration, EMA, local, etc.). In addition, after the EMA has come to a decision, new evaluation procedures in different European countries should be avoided. HTA, the multi-disciplinary field of policy analysis that studies the medical, social, ethical, and economic implications of development, diffusion, and use of health technology, 19 should include cost-effectiveness criteria but only be envisaged when necessary.
The participants of the MS Multi-stakeholder Colloquium felt that the development of a standardised MS cost-of-illness calculation model which could be applied in different countries might also increase funding for MS across Europe and as such increase the health and quality of life of people living with MS in these countries. This is further elaborated on in the paper related to this Colloquium discussing the payer's perspective. 20
Conclusion
The EMSP has clearly shown with the MS Barometer 2013 results that there are inequalities in access to care and treatment for patients living with MS in different European countries, 13 with very low access in several eastern and southern European countries. As populations across Europe are ageing, new innovative healthcare technology and treatments are becoming more expensive but healthcare budgets (due to the economic crisis) cannot increase accordingly; there is pressure on Ministries of Health and politicians to ensure that healthcare remains affordable and available budgets are spent well across (chronic) diseases. In this landscape, the EC/European Parliament has to safeguard that policies with regard to equal rights of access to care and treatment across Europe such as the European Code of Good Practice in MS 15 are not only developed but also applied and executed in the EU. However, politicians are usually no experts in healthcare with numerous often complex (chronic) diseases and cannot oversee the often long-term consequences of decisions taken today. Therefore, the different stakeholders in MS should work together to better educate society in general and policy makers in particular about the fact that MS is a very debilitating progressive disease that affects the life of over 600,000 relatively young European people with MS and their caregivers with huge costs for society due to productivity loss and high unemployment rates. This will hopefully put MS higher on their agenda and increase funds for improving the quality of care of MS patients. As such, the Under Pressure project 16 of EMSP showing how people suffering from MS deal with the disease across Europe is a very good first initiative. There is also a need for developing joint calls to action and set priorities based on which politicians can take timely and appropriate decisions. The calls to action should focus on the advantages, for example, improved patient safety, increased efficiency, better quality at lower costs for individuals and society. The numerous efforts, undertaken by the polish EMPS society PTSR, a.o. focused at communication with the Ministry of Health and the HTA agency, have shown that this can lead to success. Although governments may have a difficult task in convincing patients, physicians and other involved stakeholders about the advantages, integrated care could be an important tool to ensure access to appropriate care and treatment while still being (cost-)efficient.
